Article
Integrative & Complementary Medicine
Guan-Yu Chen, Yi-Cheng Pan, Tung-Ying Wu, Tsung-You Yao, Wei-Jan Wang, Wan-Jou Shen, Azaj Ahmed, Shu-Ting Chan, Chih-Hsin Tang, Wei-Chien Huang, Mien-Chie Hung, Juan-Cheng Yang, Yang-Chang Wu
Summary: This study identified 39 natural products from the Taiwan Database of Extracts and Compounds that can potentially prevent the binding of viral spike proteins with human ACE2 proteins, thus blocking the entry of SARS-CoV-2 into cells. In silico and in vitro experiments demonstrated the binding affinities of these natural products and their inhibitory effects on viral infection.
JOURNAL OF TRADITIONAL AND COMPLEMENTARY MEDICINE
(2022)
Article
Biochemistry & Molecular Biology
Yeh Chen, Wen-Hao Yang, Hsiao-Fan Chen, Li-Min Huang, Jing-Yan Gao, Cheng-Wen Lin, Yu-Chuan Wang, Chia-Shin Yang, Yi-Liang Liu, Mei-Hui Hou, Chia-Ling Tsai, Yi-Zhen Chou, Bao-Yue Huang, Chian-Fang Hung, Yu-Lin Hung, Wei-Jan Wang, Wen-Chi Su, Vathan Kumar, Yu-Chieh Wu, Shih-Wei Chao, Chih-Shiang Chang, Jin-Shing Chen, Yu-Ping Chiang, Der-Yang Cho, Long-Bin Jeng, Chang-Hai Tsai, Mien-Chie Hung
Summary: This study screened a library of FDA-approved compounds and identified the antimalarial drug tafenoquine (TFQ) as a potential inhibitor of the SARS-CoV-2 main protease (M-pro). The crystal structure of the M-pro-TFQ complex revealed the binding and reshaping of the substrate-binding pocket, blocking the catalytic activity. TFQ was also found to inhibit a human trans-membrane protease. A derivative of TFQ, compound 7, showed improved efficacy in inhibiting protease activity and may therefore be effective against SARS-CoV-2 and its variants.
JOURNAL OF BIOLOGICAL CHEMISTRY
(2022)
Article
Gastroenterology & Hepatology
Mincheng Yu, Zheng Chen, Qiang Zhou, Bo Zhang, Jinlong Huang, Lei Jin, Binghai Zhou, Shuang Liu, Jiuliang Yan, Xiaoqiang Li, Wentao Zhang, Chunxiao Liu, Bo Hu, Peiyao Fu, Chenhao Zhou, Yongfeng Xu, Yongsheng Xiao, Jian Zhou, Jia Fan, Ning Ren, Mien-Chie Hung, Lei Guo, Hui Li, Qinghai Ye
Summary: PARG plays an oncogenic role in HCC by modulating the PARG/DDB1/c-Myc signaling pathway. Targeting PARG in combination with anti-PD-1 therapy shows promising therapeutic efficacy in HCC.
JOURNAL OF HEPATOLOGY
(2022)
Article
Multidisciplinary Sciences
Chia-Sheng Chu, Chi-Ying Yang, Chun-Chieh Yeh, Ro-Ting Lin, Chi-Ching Chen, Li-Yuan Bai, Mien-Chie Hung, Chun-Che Lin, Chun-Ying Wu, Jaw-Town Lin
Summary: Investigating the intra-tumoral microbiome through endoscopic ultrasound-guided fine-needle biopsy (EUS-FNB) can provide adequate fresh pancreatic cancer tissue for research. This study found that the microbiome profiles obtained from EUS-FNB and surgical biopsy were comparable in terms of alpha-diversity and taxonomic composition.
SCIENTIFIC REPORTS
(2022)
Article
Cell Biology
Yunfei Wen, Anca Chelariu-Raicu, Sujanitha Umamaheswaran, Alpa M. Nick, Elaine Stur, Pahul Hanjra, Dahai Jiang, Nicholas B. Jennings, Xiuhui Chen, Sara Corvigno, Deanna Glassman, Gabriel Lopez-Berestein, Jinsong Liu, Mien-Chie Hung, Anil K. Sood
Summary: Anti-angiogenic therapies, such as anti-VEGF antibodies, have shown promise clinically but often face adaptive resistance. Research on adaptive resistance to AVA therapy in ovarian cancer models reveals mechanisms involving endothelial p130cas, VEGFR2 cleavage, and autophagy. Targeting these pathways, such as blocking autophagy or genomic ablation of vascular p130cas, can significantly improve survival in AVA-resistant ovarian tumors, providing new strategies for overcoming adaptive resistance.
Article
Gastroenterology & Hepatology
Chenhao Zhou, Jialei Weng, Yuan Gao, Chunxiao Liu, Xiaoqiang Zhu, Qiang Zhou, Chia-Wei Li, Jialei Sun, Manar Atyah, Yong Yi, Qinghai Ye, Yi Shi, Qiongzhu Dong, Yingbin Liu, Mien-Chie Hung, Ning Ren
Summary: By analyzing immune-related genes, we identified a prognostic signature that is associated with the prognosis and immunotherapy response in hepatocellular carcinoma (HCC) patients. This signature accurately predicts overall survival rates and can assist in personalized clinical management.
JOURNAL OF CLINICAL AND TRANSLATIONAL HEPATOLOGY
(2022)
Article
Oncology
Xixi Zhao, Yongkun Wei, Yu-Yi Chu, Yintao Li, Jung-Mao Hsu, Zhou Jiang, Chunxiao Liu, Jennifer L. Hsu, Wei-Chao Chang, Riyao Yang, Li-Chuan Chan, Jingkun Qu, Shuqun Zhang, Haoqiang Ying, Dihua Yu, Mien-Chie Hung
Summary: This study reveals the role of CK2 in immunosuppression by phosphorylation and stabilization of PD-L1, and suggests CK2 inhibition as a potential immunotherapeutic approach for treating cancer.
Article
Cell Biology
Yaohua Zhang, Chengcao Sun, Yajuan Li, Juan Qin, Kaushik Amancherla, Ying Jing, Qingsong Hu, Ke Liang, Zhao Zhang, Youqiong Ye, Lisa A. Huang, Tina K. Nguyen, Sergey D. Egranov, Zilong Zhao, Andrew Wu, Yutao Xi, Jun Yao, Mien-Chie Hung, George A. Calin, Jie Cheng, Bora Lim, Lorenz H. Lehmann, Joe-Elie Salem, Douglas B. Johnson, Michael A. Curran, Dihua Yu, Leng Han, Radbod Darabi, Liuqing Yang, Javid J. Moslehi, Chunru Lin
Summary: This study found that tumor-bearing mice treated with immune checkpoint inhibitors (ICIs) for cancer showed cardiovascular toxicities, including myocarditis and arrhythmia. Female mice were more susceptible to myocarditis. The down-regulation of MANF and HSPA5 in the heart tissue was associated with these cardiac effects.
SCIENCE TRANSLATIONAL MEDICINE
(2022)
Article
Biochemistry & Molecular Biology
Qiang Zhou, Yirui Yin, Mincheng Yu, Dongmei Gao, Jialei Sun, Zhangfu Yang, Jialei Weng, Wanyong Chen, Manar Atyah, Yinghao Shen, Qinghai Ye, Chia -Wei Li, Mien-Chie Hung, Qiongzhu Dong, Chenhao Zhou, Ning Ren
Summary: GTPBP4 plays a crucial role in the development of hepatocellular carcinoma by promoting aerobic glycolysis through inducing the formation and sumoylation modification of PKM2. The SUMO-modified PKM2 may contribute to HCC progression by activating epithelial-mesenchymal transition and STAT3 signaling pathway. Shikonin, a PKM2-specific inhibitor, shows promise as a therapeutic candidate for HCC patients.
Article
Oncology
Jia-Ha Yen, Wei-Chie Huang, Shu-Chin Lin, Yi-We Huang, Wan-Ting Chio, Gregory J. Tsay, Mien-Chi Hung, Sheng-Teng Huang
Summary: The study reveals that cryptotanshinone (CPT) can convert TAMs from an M2 phenotype to an M1 phenotype, leading to tumor regression. CPT inhibits mitochondrial oxidative phosphorylation and fusion through autophagy and activates the ASK1 pathway. These findings provide a new macrophage-based approach for cancer immunotherapy.
MOLECULAR THERAPY-ONCOLYTICS
(2022)
Article
Oncology
Yu-Yi Chu, Mei-Kuang Chen, Yongkun Wei, Heng-Huan Lee, Weiya Xia, Ying-Nai Wang, Clinton Yam, Jennifer L. Hsu, Hung-Ling Wang, Wei-Chao Chang, Hirohito Yamaguchi, Zhou Jiang, Chunxiao Liu, Ching-Fei Li, Lei Nie, Li-Chuan Chan, Yuan Gao, Shao-Chun Wang, Jinsong Liu, Shannon N. Westin, Sanghoon Lee, Anil K. Sood, Liuqing Yang, Gabriel N. Hortobagyi, Dihua Yu, Mien-Chie Hung
Summary: This study reveals that anaplastic lymphoma kinase (ALK) phosphorylates CDK9 at tyrosine-19, leading to homologous recombination repair and resistance to PARP inhibitors. Combining ALK and PARP inhibitors shows promising results in reducing tumor growth and improving survival. The expression of phosphorylated ALK is associated with resistance to PARP inhibitors.
Article
Chemistry, Analytical
Jaskirat Singh Batra, Ting-Yen Chi, Mo-Fan Huang, Dandan Zhu, Zheyuan Chen, Dung-Fang Lee, Jun Kameoka
Summary: This study developed a wearable paper-based virus sensor based on molecular imprinting technique and conductive polyaniline, which can detect and monitor potential virus infections. This sensor can be integrated with a face mask, offering an alternative approach to virus monitoring in communities.
Article
Oncology
Hsiao-Fan Chen, Po-Ren Hsueh, Yen-Yi Liu, Yeh Chen, Sui-Yuan Chang, Wei-Jan Wang, Chen-Shiou Wu, Ya-Min Tsai, Yu-Shu Liu, Wen-Chi Su, Yu-Chi Chou, Mien-Chie Hung
Summary: Disulfiram has shown potential as a therapy against COVID-19 by inhibiting viral replication and blocking viral entry into host cells. It has demonstrated activity against different variants of SARS-CoV-2 in molecular and cellular biology assays.
AMERICAN JOURNAL OF CANCER RESEARCH
(2022)
Article
Oncology
David J. H. Shih, Mei-Kuang Chen, Jun Yin, Daniel J. McGrail, Hui Dai, Rongbin Wei, Jing Zhang, Wenjin Jim Zheng, Kim-Anh Do, Liuqing Yang, Mien-Chie Hung, Shiaw-Yih Lin
Summary: This study developed a bioinformatic strategy for identifying candidate drugs to overcome acquired resistance in cancer treatment. By analyzing transcriptomic data and compound perturbation profiles, the authors discovered a transcriptional adaptation deficiency in resistant clones of breast cancer cells treated with PARP inhibitors. They successfully validated the vulnerability induced by this deficiency and suggested a new strategy for precision oncology.
AMERICAN JOURNAL OF CANCER RESEARCH
(2022)
Article
Medical Informatics
Lili Feng, Zhenyu Liu, Chaofeng Li, Zhenhui Li, Xiaoying Lou, Lizhi Shao, Yunlong Wang, Yan Huang, Haiyang Chen, Xiaolin Pang, Shuai Liu, Fang He, Jian Zheng, Xiaochun Meng, Peiyi Xie, Guanyu Yang, Yi Ding, Mingbiao Wei, Jingping Yun, Mien-Chie Hung, Weihua Zhou, Dantel R. Wahl, Ping Lan, Jie Tian, Xiangbo Wan
Summary: Accurate prediction of pathological complete response to neoadjuvant chemoradiotherapy for locally advanced rectal cancer was achieved using an artificial intelligence radiopathomics integrated model based on pretreatment MRI and H&E-stained biopsy slides. The model, RAPIDS, showed high accuracy and outperformed single-modality prediction models, providing a novel tool for individualized management of locally advanced rectal cancer.
LANCET DIGITAL HEALTH
(2022)
